The All Wales Medicines Strategy Group (AWMSG) has approved the use of Imnovid® (pomalidomide) for relapsed and/or refractory myeloma patients who have previously received both bortezomib and lenalidomide. The approval was based on trial data demonstrating that Imnovid, in combination with dexamethasone, significantly improved progression-free and overall survival compared to dexamethasone alone. Imnovid is also approved by the Scottish Medicines Consortium (SMC) for use in myeloma patients in Scotland. However, the National Institute for Health and Care Excellence (NICE) issued negative guidance on the drug earlier this year although patients in England can, at present, access Imnovid via the Cancer Drugs Fund.

Read full article